ESSENTIAL THROMBOCYTHEMIA
Clinical trials for ESSENTIAL THROMBOCYTHEMIA explained in plain language.
Never miss a new study
Get alerted when new ESSENTIAL THROMBOCYTHEMIA trials appear
Sign up with your email to follow new studies for ESSENTIAL THROMBOCYTHEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:55 UTC
-
Could a targeted drug boost chemo for tough blood cancers?
Disease control OngoingThis study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
Smarter CMV strategy may protect stem cell transplant patients
Disease control OngoingThis study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
New hope for rare blood cancer patients who failed standard therapies
Disease control OngoingThis study tests a drug called IMG-7289 in people with two rare blood cancers—essential thrombocythemia (ET) and polycythemia vera (PV)—that did not get better with standard treatments. The goal is to see if the drug can help control blood cell counts and reduce symptoms. The tri…
Matched conditions: ESSENTIAL THROMBOCYTHEMIA
Phase: PHASE2 • Sponsor: Terrence J Bradley, MD • Aim: Disease control
Last updated May 22, 2026 13:51 UTC